Kindred Biosciences ^{Priced, Nasdaq: KIN}

Biotech developing pet therapeutics for pain and severe itching.

Industry: Health Care

First Day Return: +70.7%

KIN

Biotech developing pet therapeutics for pain and severe itching.

IPO News for Kindred Biosciences

US IPO Recap: 221 IPOs for the year, most in a decade 12/16/13
Kindred Biosciences prices upsized IPO at the $7 midpoint 12/11/13
US IPO Recap: Hilton and eleven others set terms 12/09/13

IPO Data
IPO Date	12/11/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$53
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Burlingame, CA, United States
Founded	2012
Employees at IPO	9
Website www.kindredbio.com

IPO News for Kindred Biosciences

US IPO Recap: 221 IPOs for the year, most in a decade 12/16/13
Kindred Biosciences prices upsized IPO at the $7 midpoint 12/11/13
US IPO Recap: Hilton and eleven others set terms 12/09/13

Kindred Biosciences (KIN) Performance